Dr. Demirjian is President and CEO of zuChem, Inc. and President of the Midwest Bioprocessing Center, LLC.

At zuChem he oversaw the development of the Company’s xylitol bioprocess technology and commercialization, now being used at multi-thousand-ton scale. Prior to founding zuChem, Dr. Demirjian was previously President and Co-Founder of ThermoGen, Inc. - a bioprocessing company that pioneered chiral biocatalysis technologies for pharmaceutical applications.

He is a previous winner of the Research Director’s
Association of Chicago “Entrepreneur of the Year Award” (1997) and recipient of the U.S. SBA “Tibbets Award” for successful commercialization of technology developed under the Federal SBIR grant program. Dr. Demirjian became VP of Technology Strategy for
MediChem Life Sciences after their acquisition of ThermoGen (May 2000) and oversaw the development of MediChem’s R&D technology platform.

Dr. Demirjian helped lead MediChem’s $52MM IPO (Oct. 2000) and was a Director until its acquisition by deCODE Genetics (May 2002). He holds a Ph.D. in Genetics from The University of Chicago and a B.S.A. from the University of Michigan.